Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis.

ABSTRACT:

Objective

To evaluate pathological complete response as a surrogate endpoint for disease-free survival and overall survival in regulatory neoadjuvant trials of early stage breast cancer.

Design

Systematic review and meta-analysis.

Data sources

Medline, Embase, and Scopus to 1 December 2020.

Eligibility criteria for study selection

Randomised clinical trials that tested neoadjuvant chemotherapy given alone or combined with other treatments, including anti-human epidermal growth factor 2 (anti-HER2) drugs, targeted treatments, antivascular agents, bisphosphonates, and immune checkpoint inhibitors.

Data extraction and synthesis

Trial level associations between the surrogate endpoint pathological complete response and disease-free survival and overall surviv

SUBMITTER: Conforti F 

PROVIDER: S-EPMC8689398 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature